Euretos has expanded the coverage of Euretos Knowledge Platform to include 65 major public life sciences data and publication sources. The company has significantly accelerated the ability to add new data sources and expects to hit the 100-sources mark during the second quarter of 2016. This makes the Euretos Knowledge platform the broadest and fastest-growing knowledge base in the life sciences.
“We provide life scientists in clinical diagnostics and therapy development with better answers to research questions. Faster.” says Aram Krol, Head of Product Management at Euretos. “Providing access to all the major data and publication sources in the life sciences is essential to achieving this. We have now perfected the technology to add sources, interlink these within the knowledge base and make them instantly available to all our applications. We can now add new sources within hours. This is truly a step change in the field of applied bioinformatics and computational biology.”
The Euretos Knowledge Platform is an innovative computational biology platform used by some of the world’s largest pharma & biotech companies, academic hospitals and research institutes. The platform integrates public and, on customer request, private/proprietary data into a consolidated data source. On top of its unique knowledge base, the Euretos Knowledge platform supports powerful embedded (predictive) analytics that are too resource intensive to run in traditional environments. At any stage, the researcher has easy access to all supporting references to review and assess the available evidence personally.
“It is the combination of the scope of our knowledge base, together with the on board analytics and the ability to easily verify each underlying statement, that provide unique capabilities to life scientists” says Krol. “In the area of preclinical therapy development, for instance, we offer very powerful applications that enable researchers to evaluate all major aspects of efficacy, safety and druggability simultaneously to discover promising drug targets or biomarkers”.
The ability to guide researchers to discover novel therapeutic targets or biomarkers is regularly confirmed through recent scientific discoveries in various disease areas, such as: breast cancer, pancreatic cancer, chronic kidney disease and traumatic brain injury.